Are the benefits of NSAIDs to decrease the risk of Alzheimer's disease a MIRAGE?. Issue 3 (May 2005)

• Record Type: Journal Article
• Authors: Standridge, John B
• Is Part Of: Therapy. Volume 2:Issue 3(2005)
• Page Start: 375
• Page End: 380
• Publication Date: 2005-05
• Subjects: Alzheimers disease -- nonsteroidal anti-inflammatory drugs -- NSAIDs -- prevention -- risk reduction; Therapeutics -- Periodicals; Chemotherapy -- Periodicals; 615.505
• DOI: 10.2217/14750708.2.3.375
• Languages: English
• ISSNs: 1475-0708

Abstract

Evaluation of: Yip AG, Green RC, Huyck M et al . Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study. BMC Geriatr . 5(1), 2 (2005). The Multi-Institutional Research in Alzheimer''s Genetic Epidemiology study data reveal an inverse association between nonsteroidal anti-inflammatory drugs (NSAIDs) and Alzheimer''s disease that is more robust among subjects who carried the apolipoprotein E εε4 allele. Randomized trials of NSAIDs for the primary prevention of Alzheimer''s disease are unlikely to show effects with treatment until participants have been followed for several years. Inhibition of γγ-secretase, as identififed in three Aββ-lowering NSAIDs, is an avenue of research likely to demonstrate preventive efficacy in prospective clinical trials. A subset of NSAIDs, or their analogs, will probably contribute to a combination-therapy approach targeted to different mechanisms of the neuropathology associated with the amyloid cascade.